{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:57Z","timestamp":1707524217612},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,26]]},"DOI":"10.7759\/cureus.15250","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:25:45Z","timestamp":1622031945000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinically Worsening Myasthenia-Related Respiratory Distress Notwithstanding Normal Markers of Respiratory Function"],"prefix":"10.7759","author":[{"given":"Hamza","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Vayzband","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Myasthenia gravis","author":"Suresh AB","year":"2021","unstructured":"Suresh AB, Asuncion RMD. Myasthenia gravis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli MN","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009, 8:475-90. 10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00131402-200209000-00009","article-title":"On the concept of myasthenic crisis","volume":"4","author":"Bedlack RS","year":"2002","unstructured":"Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis. 2002, 4:40-2. 10.1097\/00131402-200209000-00009","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell LC","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011, 1:16-22. 10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"key":"ref5","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen JC","year":"2015","unstructured":"Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015, 2:73-85.","journal-title":"J Neuromuscul Dis"},{"key":"ref6","unstructured":"Clinical Overview of MG. (2015). Accessed. May 16, 2021: https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","author":"Andersen JB","year":"2014","unstructured":"Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014, 26-31. 10.1111\/ane.12233","journal-title":"Acta Neurol Scand Suppl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000415","article-title":"Myasthenia gravis and Lambert-Eaton Myasthenic syndrome","volume":"22","author":"Nicolle MW","year":"2016","unstructured":"Nicolle MW. Myasthenia gravis and Lambert-Eaton Myasthenic syndrome. Continuum (Minneap Minn). 2016, 22:1978-2005. 10.1212\/CON.0000000000000415","journal-title":"Continuum (Minneap Minn)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot J","year":"1997","unstructured":"Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med. 1997, 25:1228-35. 10.1097\/00003246-199707000-00027","journal-title":"Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:3:3:213","article-title":"Risk of extubation failure in patients with myasthenic crisis","volume":"3","author":"Rabinstein AA","year":"2005","unstructured":"Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005, 3:213-5. 10.1385\/NCC:3:3:213","journal-title":"Neurocrit Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi RR","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019, 60:693-9. 10.1002\/mus.26689","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones SC","year":"2011","unstructured":"Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011, 34:839-47. 10.2165\/11593110-000000000-00000","journal-title":"Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri A","year":"2009","unstructured":"Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009, 102:97-107. 10.1093\/qjmed\/hcn152","journal-title":"QJM"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF01711545","article-title":"The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis","volume":"21","author":"Rieder P","year":"1995","unstructured":"Rieder P, Louis M, Jolliet P, Chevrolet JC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med. 1995, 21:663-8. 10.1007\/BF01711545","journal-title":"Intensive Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829595","article-title":"Myasthenia gravis: management of myasthenic crisis and perioperative care","volume":"24","author":"Juel VC","year":"2004","unstructured":"Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004, 24:75-81. 10.1055\/s-2004-829595","journal-title":"Semin Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An official American Thoracic Society Technical Statement","volume":"196","author":"Culver BH","year":"2017","unstructured":"Culver BH, Graham BL, Coates AL, et al.. Recommendations for a standardized pulmonary function report. An official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017, 196:1463-72. 10.1164\/rccm.201710-1981ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:3:3:189","article-title":"Myasthenic crisis","volume":"3","author":"Lacomis D","year":"2005","unstructured":"Lacomis D. Myasthenic crisis. Neurocrit Care. 2005, 3:189-94. 10.1385\/NCC:3:3:189","journal-title":"Neurocrit Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas CE","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, et al.. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997, 48:1253-60. 10.1212\/wnl.48.5.1253","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos P","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997, 41:789-96. 10.1002\/ana.410410615","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann JD","year":"1976","unstructured":"Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology. 1976, 26:729-40. 10.1212\/wnl.26.8.729","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60504-clinically-worsening-myasthenia-related-respiratory-distress-notwithstanding-normal-markers-of-respiratory-function","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:46Z","timestamp":1707506986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60504-clinically-worsening-myasthenia-related-respiratory-distress-notwithstanding-normal-markers-of-respiratory-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.15250","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}